Cargando…
SapC–DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents
Glioblastoma multiforme (GBM), the most common type of brain cancer, is extremely aggressive and has a dreadful prognosis. GBM comprises 60% of adult brain tumors and the 5 year survival rate of GBM patients is only 4.3%. Standard-of-care treatment includes maximal surgical removal of the tumor in c...
Autores principales: | Kaynak, Ahmet, Davis, Harold W., Vallabhapurapu, Subrahmanya D., Pak, Koon Y., Gray, Brian D., Qi, Xiaoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619974/ https://www.ncbi.nlm.nih.gov/pubmed/34832975 http://dx.doi.org/10.3390/ph14111193 |
Ejemplares similares
-
Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles
por: Davis, Harold W., et al.
Publicado: (2020) -
Enhanced phosphatidylserine-selective cancer therapy with irradiation and SapC-DOPS nanovesicles
por: Davis, Harold W., et al.
Publicado: (2019) -
SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma
por: Blanco, Víctor M., et al.
Publicado: (2015) -
Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors
por: Blanco, Víctor M., et al.
Publicado: (2014) -
SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas
por: Sulaiman, Mahaboob K, et al.
Publicado: (2015)